GeneDx Aktie News

GeneDx shares have collapsed 65% since November, but I assign a buy rating due to strong volume growth and undervaluation versus peers. Despite a 34% YoY volume increase, revenue growth lagged at 27% due to lower reimbursement rates from a shift to genome testing. WGS owns one of the largest rare disease genomic databases, creating a durable competitive advantage and potential for AI-driven val...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos & Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).  Captioned Basma v.

PHILADELPHIA, June 10, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Barrack Rodos & Bacine filed a class action lawsuit seeking to represent purchasers of GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).  Captioned Basma v. GeneDx Holdings Corp., No. 26-cv-00880 (D. Conn.), the lawsuit charges GeneDx and certain of its top exe...

NEW YORK, June 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.

SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a sin...

During the first quarter of 2026, the largest portfolio sector weightings were Health Care and Industrials. RBC Bearings Incorporated, Cognex Corporation and Nebius Group were among the top contributors to performance. Repligen Corporation, Agilysys, Inc., and GeneDx Holdings Corp. were among the top detractors from performance.

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- Investors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a massive Q1 2026 earnings miss, a tenfold increase in net loss, and a drastic reduction in full-year 2026 guidance. The stock's move lower wiped out over $900 million from GeneDx's market capitalization in a sin...